↓ Skip to main content

Dove Medical Press

Article Metrics

Cerebrospinal fluid biomarkers for Alzheimer’s disease: the role of apolipoprotein E genotype, age, and sex

Overview of attention for article published in Neuropsychiatric Disease and Treatment, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
2 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
25 Mendeley
Title
Cerebrospinal fluid biomarkers for Alzheimer’s disease: the role of apolipoprotein E genotype, age, and sex
Published in
Neuropsychiatric Disease and Treatment, December 2015
DOI 10.2147/ndt.s95018
Pubmed ID
Authors

Shima Mehrabian, Panos Alexopoulos, Marion Ortner, Latchezar Traykov, Timo Grimmer, Alexander Kurz, Hans Förstl, Horst Bickel, Janine Diehl-Schmid

Abstract

Cerebrospinal fluid (CSF) biomarkers improve the diagnostic accuracy for Alzheimer's disease (AD), even at the predementia stage of the disease. The ε4-allele of apolipoprotein E (ApoE ε4), female sex, and older age are well-known risk factors for AD. It is unclear how these risk factors affect the CSF biomarkers in patients with AD. The objective of this study was to investigate the associations of ApoE ε4, sex, and age with CSF biomarker levels in a unicenter sample of patients with AD that includes a high proportion of patients with early-onset AD (EOAD). The CSF levels of amyloid-β 1-42 (Aβ1-42) and total-tau of 117 subjects with mild to moderate AD (55 late-onset AD and 62 EOAD) were assessed. All subjects underwent ApoE genotyping, clinical evaluation, comprehensive neuropsychological assessments, and neuroimaging. Associations between CSF biomarker levels, ApoE ε4 allele frequency, age, and sex were evaluated. In the whole patient sample and in the late-onset AD subgroup ε4 homozygous subjects had significantly lower CSF Aβ1-42 levels compared with ε4 heterozygous subjects and ε4 noncarriers. This association was not detected in the EOAD group. Age group, sex, and severity of cognitive decline did not have a significant impact on CSF Aβ1-42 levels. No significant associations were found between ApoE ε4 allele frequency and CSF total-tau levels. ApoE ε4 allele is associated with a reduction of CSF Aβ1-42 levels. This result is consistent with the findings of several previous studies. In the subgroup of patients with EOAD this association was not replicated. Larger studies are necessary to further investigate associations between ApoE ε4 allele frequency and CSF biomarker levels in patients with EOAD.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 4%
Austria 1 4%
Brazil 1 4%
Unknown 22 88%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 24%
Researcher 4 16%
Student > Bachelor 3 12%
Student > Ph. D. Student 3 12%
Student > Doctoral Student 2 8%
Other 4 16%
Unknown 3 12%
Readers by discipline Count As %
Medicine and Dentistry 10 40%
Agricultural and Biological Sciences 2 8%
Chemistry 2 8%
Neuroscience 2 8%
Psychology 1 4%
Other 3 12%
Unknown 5 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2016.
All research outputs
#2,706,509
of 22,835,198 outputs
Outputs from Neuropsychiatric Disease and Treatment
#361
of 2,986 outputs
Outputs of similar age
#47,195
of 387,565 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#5
of 61 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,986 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,565 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.